JNJ Stock Rallies on FDA Approval: Analyst Upgrades Signal Healthcare Strength

# Johnson & Johnson Stock Analysis: FDA Approval Drives Bullish Momentum Despite Trading Dip | JNJ Stock Update March 2024 Johnson & Johnson (NYSE: JNJ) stock closed at $237.28 on March 18th, experiencing a modest 0.4% decline amid lower-than-average trading volume. This podcast episode provides comprehensive coverage of JNJ's recent market performance, including groundbreaking FDA approval news and multiple analyst upgrades. **Key highlights include:** - **Major FDA Approval:** J&J's oral psoriasis pill receives FDA clearance, with Guggenheim projecting over $8 billion in peak annual sales - **Analyst Upgrades:** Goldman Sachs reiterates buy rating with $265 price target; HSBC raises target to $280; Royal Bank of Canada and JPMorgan also increase price targets - **Bullish Sentiment Indicators:** Short interest dropped 17.55% to 18.18 million shares, suggesting positive investor outlook - **Market Fundamentals:** $571.2 billion market cap, 52-week range of $141.50-$251.71 This episode examines why leading financial institutions including Barclays, Goldman Sachs, HSBC, and Royal Bank of Canada are showing increased confidence in JNJ stock, despite recent trading volume dips. Perfect for investors tracking pharmaceutical stocks, healthcare sector investments, and dividend blue-chip opportunities. Subscribe for regular stock market analysis, healthcare industry insights, and JNJ investment updates. *A Quiet Please production - Visit quietplease.ai for more financial podcasts* **Keywords:** Johnson & Johnson stock, JNJ stock analysis, pharmaceutical stocks, FDA approval news, healthcare investing, stock market podcast, analyst ratings, psoriasis treatment For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.